{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "PARK2 mutations in cancer decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of E3 ligase activity leading to impaired ubiquitination of cyclin E, which contributes to mitotic instability and tumor growth in cancer."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We used a well-established assay to measure the ubiquitination function of PARK2 mutants in cells. Cancer-specific mutations in PARK2 were found to substantially compromise the association of PARK2 with ubiquitinated target proteins in cancer cells.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay used is a well-established method in the field to assess E3 ligase activity, directly relevant to the disease mechanism of PARK2 in cancer (loss of ubiquitination leading to cyclin E accumulation).",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Transfection of WT but not mutant PARK2 into cells from the DBTRG line resulted in a reduction in the rate of cell growth. All experiments were performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of wild-type PARK2 as a control and explicitly states that experiments were performed in triplicate, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "No explicit mention of known pathogenic or benign variant controls used in the assays for comparison with the cancer-specific mutations.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variants as controls in the functional assays for this variant, nor does it reference variants reaching P/LP or B/LB criteria without PS3/BS3 reliance.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R42P supports a pathogenic role with a strength of PS3_supporting. This is based on the clear definition of disease mechanism, applicability of the ubiquitination assay, and presence of basic controls and replicates. However, the lack of variant-specific controls limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "W",
          "position": "275"
        },
        "variant_string_id": "PARK2 R275W"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "PARK2 mutations in cancer decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of E3 ligase activity leading to impaired ubiquitination of cyclin E, which contributes to mitotic instability and tumor growth in cancer."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We used a well-established assay to measure the ubiquitination function of PARK2 mutants in cells. Cancer-specific mutations in PARK2 were found to substantially compromise the association of PARK2 with ubiquitinated target proteins in cancer cells.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay used is a well-established method in the field to assess E3 ligase activity, directly relevant to the disease mechanism of PARK2 in cancer (loss of ubiquitination leading to cyclin E accumulation).",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Transfection of WT but not mutant PARK2 into cells from the DBTRG line resulted in a reduction in the rate of cell growth. All experiments were performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of wild-type PARK2 as a control and explicitly states that experiments were performed in triplicate, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "No explicit mention of known pathogenic or benign variant controls used in the assays for comparison with the cancer-specific mutations.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variants as controls in the functional assays for this variant, nor does it reference variants reaching P/LP or B/LB criteria without PS3/BS3 reliance.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 R275W supports a pathogenic role with a strength of PS3_supporting. This is based on the clear definition of disease mechanism, applicability of the ubiquitination assay, and presence of basic controls and replicates. However, the lack of variant-specific controls limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "E",
          "alt": "G",
          "position": "344"
        },
        "variant_string_id": "PARK2 E344G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "PARK2 mutations in cancer decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of E3 ligase activity leading to impaired ubiquitination of cyclin E, which contributes to mitotic instability and tumor growth in cancer."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We used a well-established assay to measure the ubiquitination function of PARK2 mutants in cells. Cancer-specific mutations in PARK2 were found to substantially compromise the association of PARK2 with ubiquitinated target proteins in cancer cells.",
          "judgment": "Yes",
          "reasoning": "The ubiquitination assay used is a well-established method in the field to assess E3 ligase activity, directly relevant to the disease mechanism of PARK2 in cancer (loss of ubiquitination leading to cyclin E accumulation).",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Transfection of WT but not mutant PARK2 into cells from the DBTRG line resulted in a reduction in the rate of cell growth. All experiments were performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "The paper mentions the use of wild-type PARK2 as a control and explicitly states that experiments were performed in triplicate, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "No explicit mention of known pathogenic or benign variant controls used in the assays for comparison with the cancer-specific mutations.",
          "judgment": "No",
          "reasoning": "The paper does not mention the use of known pathogenic or benign variants as controls in the functional assays for this variant, nor does it reference variants reaching P/LP or B/LB criteria without PS3/BS3 reliance.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for PARK2 E344G supports a pathogenic role with a strength of PS3_supporting. This is based on the clear definition of disease mechanism, applicability of the ubiquitination assay, and presence of basic controls and replicates. However, the lack of variant-specific controls limits the strength to supporting."
    }
  ]
}